Media Release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide achieves strong profitable growth in 2021
Zug, 15 March 2022 – PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results for the financial year 2021:
Raymond De Vré, Chief Executive Officer of PolyPeptide, commented:
“We delivered strong sales growth of over 25% with a consistently high delivery performance in what was an exceptional year for PolyPeptide, also completing the IPO back in April 2021. Our results reflect well on PolyPeptide’s technical capabilities, execution mindset and customer focus. We remain committed to long-term relationships, as we partner with our customers on the development and commercialization of their therapeutic products – in peptides and increasingly also in oligonucleotides. I look forward to continuing to work with our customers and in doing so, to contribute to the health of millions of patients around the world.”
The necessary cookies help to make a website usable by enabling basic functions such as page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
Marketing cookies are used to track visitors through websites. The goal is to display ads that are relevant and interesting to the individual user and therefore more valuable to third-party publishers and advertisers.
Statistical cookies help website owners, through the anonymous collection and communication of information, to understand how visitors interact with websites.
Preferences cookies allow a website to retain information that changes the way the site behaves or displays, such as your preferred language or the region in which you are located.